New fund will continue Medicxi’s successful asset-centric company creation and investment strategy. LONDON, UK — November 14, 2025 — Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The […]
Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics […]
Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly experienced executive with deep scientific expertise, who has helped lead numerous private and public cell therapy biotechs, establishing corporate structures and raising funds Appointment comes as Blue Cell advances its groundbreaking “off-the-shelf” allogeneic […]
Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very favourable safety profile Commit Biologics’ CEO Mikkel Wandahl Pedersen to present data at PEGS Europe summit, November 11-13, 2025 in Lisbon, Portugal Aarhus, Denmark, November […]
Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control observed in multiple patients at lowest dose evaluated to date Enrolment continues in dose-escalation segment of the AERIAL trial with additional data for LEU011 anticipated during the first half of 2026 Poster presentation of AERIAL trial […]
